GlassScriptPhysician profile
Raafat S Iskander
NPI 1407958234
$17,123.99
in general payments reported to CMS, 2019-2025
38 companies · $2,482 in 2025
The $2,482 reported for 2025 was more than what 76% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,334 · 2020: $1,796 · 2021: $2,216 · 2022: $2,235 · 2023: $1,863 · 2024: $2,199 · 2025: $2,482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,544.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,543.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $2,534.48 | 2019-2025 | Fintepla, Nayzilam, Zilbrysq |
| Supernus Pharmaceuticals, INC. | $1,693.52 | 2019-2022 | |
| Biogen, INC. | $1,588.30 | 2019-2025 | Vumerity, Tysabri, Leqembi |
| Sunovion Pharmaceuticals INC. | $1,439.77 | 2019-2022 | |
| Aquestive Therapeutics, INC. | $1,078.66 | 2019-2022 | |
| Eisai INC. | $1,015.66 | 2019-2025 | |
| Greenwich Biosciences, INC. | $1,009.74 | 2019-2021 | |
| Sk Life Science, INC. | $946.87 | 2020-2025 | Xcopri |
| Neurelis, INC. | $943.74 | 2020-2025 | Valtoco |
| Sumitomo Pharma America, INC. | $929.80 | 2023-2024 | Aptiom |
| Amneal Pharmaceuticals LLC | $753.22 | 2019-2025 | Rytary, Crexont |
| Harmony Biosciences LLC | $723.16 | 2020-2025 | Wakix |
| Livanova USA, INC. | $425.38 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Catalyst Pharmaceuticals, INC. | $369.07 | 2023-2025 | Fycompa |
| Novartis Pharmaceuticals Corporation | $254.71 | 2019-2020 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raafat Iskander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.